SureTrader Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: buythebuy
Search This Board:
Last Post: 7/29/2016 7:03:09 PM - Followers: 170 - Board type: Free - Posts Today: 10


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Current Report Filing (8-k) 07/28/2016 04:03:53 PM
USRM News: Statement of Ownership (sc 13g) 07/15/2016 06:04:58 AM
USRM News: Statement of Ownership (sc 13g) 06/21/2016 06:04:09 AM
USRM News: Statement of Ownership (sc 13g) 06/08/2016 06:06:14 AM
USRM News: Statement of Ownership (sc 13g) 05/26/2016 11:42:40 AM
#17044  Sticky Note USRM LATEST PRESS RELEASE! buythebuy 06/25/16 11:39:49 AM
#17151   USRM has lots going for it. buythebuy 07/29/16 07:03:09 PM
#17150   I tend to agree with you on that. buythebuy 07/29/16 06:59:36 PM
#17149   Two New Clinical Development in the Pipeline H20-Life 07/29/16 05:25:17 PM
#17148   Clinical Development Pipeline H20-Life 07/29/16 05:24:34 PM
#17147   My guess, Ahn will be replaced with a H20-Life 07/29/16 05:23:43 PM
#17146   Agreed. I also say no one man stops buythebuy 07/29/16 10:36:23 AM
#17145   He's still the President and CEO of Vascular Investaholic33 07/29/16 10:34:09 AM
#17144   You never know but I am sure if buythebuy 07/29/16 10:32:15 AM
#17143   It's a bad sign that Ahn resigned. Poor Man - 07/29/16 10:02:09 AM
#17142   I would be more concerned about USRM if buythebuy 07/29/16 07:49:37 AM
#17141   No wonder the stock dropped togmaster 07/28/16 11:54:26 PM
#17140   8-K filing..Board Member RESIGNS... Hornet Driver 07/28/16 05:22:56 PM
#17139   Bammo... AEXG on the Ask Hornet Driver 07/28/16 02:34:51 PM
#17138   Looks like USRM's spread has tightened up at buythebuy 07/28/16 09:50:23 AM
#17137   Government Support Crucial for Widespread Adoption of Stem H20-Life 07/28/16 04:06:08 AM
#17136   Global Market for Regenerative Medicine & Stem Cells H20-Life 07/28/16 04:02:28 AM
#17135   Stem Cell Banking Market Worth 3.96 Billion USD H20-Life 07/28/16 04:01:52 AM
#17134   It was an interesting day for USRM. Let's buythebuy 07/27/16 08:29:54 PM
#17133   0.022 / 0.026 Bid and Ask..UH OH !! Hornet Driver 07/27/16 12:33:35 PM
#17132   USRM could do it but with 3 green buythebuy 07/27/16 06:12:08 AM
#17131   Lots of buying at the end of the togmaster 07/26/16 07:32:31 PM
#17130   Quote LOL, "It will be interesting to see Hornet Driver 07/26/16 10:14:01 AM
#17129   It will be interesting to see what USRM buythebuy 07/26/16 09:21:57 AM
#17128   Yes indeed especially for a Monday. Solid day buythebuy 07/25/16 08:56:02 PM
#17127   Nice day OTCRIDDLER 07/25/16 08:50:37 PM
#17126   Nice volume for USRM today. buythebuy 07/25/16 10:32:22 AM
#17125   It will be interesting to see what USRM buythebuy 07/25/16 07:25:55 AM
#17124   I agree OTCRIDDLER 07/25/16 07:22:11 AM
#17123   Ok, think about this no matter what the buythebuy 07/25/16 06:25:58 AM
#17121   Quote LOL, "The float is extremely low and Hornet Driver 07/24/16 09:52:47 PM
#17120   I think you are being very realistic short buythebuy 07/24/16 06:18:35 PM
#17118   Seems to me that warning letter link is buythebuy 07/24/16 05:45:38 PM
#17117   Very positive DD for USRM indeed. buythebuy 07/24/16 05:42:02 PM
#17116   I read both posts the one you wrote buythebuy 07/24/16 05:40:32 PM
#17115   Quote LOL, "USRM patient testimonials link. " Hornet Driver 07/24/16 05:36:14 PM
#17114   Nobel Prize Winner H20-Life 07/24/16 04:40:35 PM
#17113   After the Nobel: A stem cell crusader awakens H20-Life 07/24/16 04:38:38 PM
#17112   Research report explores the market analysis on stem H20-Life 07/24/16 04:35:16 PM
#17111   "The staff was excellent and quickly answered any H20-Life 07/24/16 04:21:04 PM
#17110   U.S. Stem Cell Announces Positive Results for Traumatic H20-Life 07/24/16 04:06:19 PM
#17109   I think this. Chart reminded me of $ONO-V OTCRIDDLER 07/24/16 02:23:01 PM
#17108   Excellent post. I have been thinking of richme 07/24/16 01:59:27 PM
#17107   USRM patient testimonials link. buythebuy 07/24/16 10:26:09 AM
#17106   Video showing USRM'S Kristen Comella speaking on stem buythebuy 07/24/16 10:15:25 AM
#17105   Yes, that is interesting and USRM bounced on buythebuy 07/22/16 08:23:59 PM
#17103   Bid at 1.25 CENTS..NEW ALL TIME LOW Hornet Driver 07/21/16 03:46:16 PM
#17102   Looks like USRM is trying it's best to buythebuy 07/20/16 09:11:47 AM
#17101   And BAMMO...there goes the Bid Hornet Driver 07/18/16 01:51:28 PM
#17100   Options strike price range $2.72 - $1,270.73 H20-Life 07/18/16 12:12:21 AM
#17099   After all that is said and done with H20-Life 07/18/16 12:11:39 AM